The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

GLP-1 medications have been shown to improve health and offer strong value for their price, yet many insurance plans continue to restrict access. Researchers at the University of Mississippi are investigating the financial and practical reasons behind those limits, along with the consequences…

Click here to view the original article.